United Kingdom

People: Constellation Pharmaceuticals Inc (CNST.OQ)

CNST.OQ on NASDAQ Stock Exchange Global Select Market

8:14pm BST
Change (% chg)

$-0.53 (-7.04%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Christo, Jessica 

Ms. Jessica Christo is Chief Product Development Officer of the company. Ms. Christo brings to Constellation 25 years of product development experience in the biopharmaceutical industry. Most recently, she was Senior Vice President of Development Operations at Verastem Oncology, where she was responsible for clinical operations, data management, biostatistics, medical writing, safety, regulatory affairs, program planning and management, and translational medicine. While at Verastem, she contributed to the recent approval of COPIKTRA TM . Prior to Verastem, she held positions of increasing responsibility in clinical operations and program management at X4 Pharmaceuticals, Molecular Insight Pharmaceuticals, Fresenius Biotech, Taris Biomedical, and CombinatoRx. Earlier in her career she was a biostatistician at several pharmaceutical/medical device companies, notably Millennium Pharmaceuticals, where she contributed to the development and approval of VELCADE®. She holds an M.A. in statistics from Texas Tech University.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --